medRxiv
November 17, 2025
Georgia Ioakimidis-Macdougall, John Gardner, Paul Liknaitzky
preprint
A single 25 mg dose of psilocybin, given with psychological support in a clinical setting, helped 14 mental health professionals develop a greater embodied understanding of therapeutic principles and processes. Participants reported increases in empathy, attunement, and emotion regulation—qualities that underpin therapeutic alliance and promote trust and safety. While no harms were reported, participants noted two potential risks: the experience could feel destabilizing, and therapists might project their own experience onto clients, narrowing interpretative range. Participants indicated that such training is necessary but not sufficient for high-quality psychedelic-assisted therapy. Findings support including an optional psychedelic experiential component for clinicians with prior training and reflective capacity.
medRxiv
August 28, 2025
Franziska Stadler, Johan Saelens, Ioline D. Henter et al.
preprint
An international online study of 759 people examined how psychedelic drug use affects cognitive performance and mental health in the short and long term. Participants completed tasks measuring working memory, selective attention, and visual/spatial perception, plus questionnaires on mental health and quality of life. Recent users showed significantly lower accuracy on all cognitive tasks and reported more depressive and dissociative symptoms. Lifetime users had the highest task accuracy without slower reaction times, and their use was not linked to long-term cognitive decline. However, lifetime users scored lower on psychological and social quality of life domains, suggesting possible long-term psychosocial effects.
medRxiv
August 16, 2025
S. Parker Singleton, Brooke L. Sevchik, Analiese Lahey et al.
preprint
Psilocybin-assisted therapy produces substantial reductions in depressive symptoms compared to control conditions, according to a systematic review and meta-analysis of 12 randomized controlled trials with 711 participants. The pooled effect size was large (Hedges' g = –0.91), and effects appeared rapidly and remained consistent over several weeks. However, many studies had small sample sizes or risk of bias, and waitlist-controlled or crossover designs contributed heterogeneity. The review provides a living open data resource that will be updated as new evidence emerges.
medRxiv
August 7, 2025
Ben Deverett, Duan Li, Theresa R. Lii et al.
preprint
Ketamine produces dissociative, analgesic, and antidepressant effects, but it is unclear whether its underlying neurophysiological signatures can be separated. In this observational cohort study, 52 participants (healthy volunteers, elective surgery patients, and patients with depression) received a subanesthetic infusion of ketamine or placebo, with or without general anesthesia. When ketamine was given under general anesthesia, its characteristic low-frequency brain wave augmentation was absent, while high-frequency power modulation was preserved. This selective modulation suggests a method for investigating the distinct roles of high- and low-frequency neural activity in ketamine's behavioral effects.
medRxiv
July 29, 2025
Artemis Zavaliangos‐petropulu, Ginny Ghang, Toni Boltz et al.
preprint
Treatment-resistant depression affects 30-50% of people with major depressive disorder. Electroconvulsive therapy and ketamine can relieve it, but how they work is unclear. This transcriptome analysis of peripheral blood from 37 people receiving electroconvulsive therapy, 60 receiving ketamine, and 35 non-depressed controls found no longitudinal changes in gene expression for either treatment after correcting for multiple comparisons. In the ketamine group, one gene (IGKV1-9) differed between remitters and non-remitters at baseline. In the electroconvulsive therapy group, six co-regulated gene modules differed at baseline between patients and controls. Pre-treatment gene expression differences may have predictive value, but larger studies are needed.
medRxiv
July 29, 2025
Yuwen He, Shan Lei, Wangli Si et al.
preprint
Mindfulness meditation training alters functional connectivity in the somatomotor network (SMN) in both healthy and depressed populations. In 51 healthy and 35 depressed participants, common changes involved SMN-attentional network connections, suggesting that training modulates attention through somatic awareness. Population-specific changes also emerged: healthy individuals showed SMN-subcortical network shifts, indicating more pervasive effects on automatic processes, while depressed individuals showed SMN-default mode network interactions, which may explain why mindfulness is effective for depression. These altered connectivity patterns significantly predicted insomnia improvements after training in both groups, highlighting shared and distinct neural mechanisms underlying mindfulness-related mental health benefits.
medRxiv
June 18, 2025
Drummond E-Wen Mcculloch, K. M. Larsen, Annette Johansen et al.
preprint
Lysergic acid diethylamide (LSD) increases global cerebral blood flow and internal carotid artery flow without affecting artery diameter, effects opposite to those of psilocybin. Functional connectivity analyses show decreases in global connectivity (GCOR), which is negatively correlated with the increase in cerebral blood flow. An anticlockwise hysteresis loop between plasma drug levels and subjective effects suggests atypical pharmacodynamic mechanisms. These findings, derived from simultaneous PET-MRI in seven healthy volunteers, establish the dose-occupancy relation of LSD at cerebral serotonin 2A receptors and highlight neurophysiological differences from related psychedelics, providing insights for clinical development.
medRxiv
February 21, 2025
Alene Sze Jing Yong, Sue Brennan, Suzie Bratuskins et al.
preprint
Australia's Therapeutic Goods Administration rescheduled MDMA in July 2023, allowing its prescription for PTSD outside clinical trials. This manuscript outlines the development of an Australian Clinical Practice Guideline on MDMA-assisted psychotherapy for PTSD, using the GRADE process to weigh benefits and harms against other treatments. A multidisciplinary Guideline Development Group, supported by stakeholder and expert groups, will consider evidence certainty, patient values, resources, equity, acceptability, and feasibility. The guideline will be published on MAGICapp and in peer-reviewed outlets, with a companion guide for people with PTSD and their carers.
medRxiv
February 7, 2025
Andrew G. Breithaupt, Georges Naasan, Suzanne M. Shdo et al.
preprint
Psychosis is a common and burdensome symptom in neurodegenerative diseases. Analyzing 283 autopsy-confirmed cases, delusions were linked to atrophy in the right temporal lobe and bilateral frontal lobes, especially when persecutory or paranoid, implicating circuits for reward, emotion, self-awareness, and executive function. Misidentification delusions correlated with right ventral temporal-occipital atrophy, disrupting visual stream processing. No consistent atrophy patterns emerged with hallucinations. Damage to these brain regions predisposes individuals to delusions across different syndromes and pathologies, suggesting shared mechanisms between neurologic and psychiatric disorders.
medRxiv
October 13, 2024
Brian S. Barnett
preprint
A survey of researchers who published the most-cited psychedelics articles since 2000 found that federal grant applications for therapeutic psychedelic research at the National Institutes of Health (NIH) had a 16.7% funding rate, lower than the NIH's 23.4% average for R-01 equivalent grants from 1998 to 2023. No applications submitted before 2006–2010 were funded, but the rate since then (estimated at 19.05% to 22.2%) is close to the NIH's average annual rate of 20.6% for those years. Respondents believed the funding landscape has improved recently.
medRxiv
June 20, 2024
Dimy Fluyau, Vasanth Kattalai Kailasam, Neelambika Revadigar
preprint
Psilocybin produced a rapid and sustained reduction in depressive and anxiety symptoms in patients with major depressive disorder and in those with life-threatening cancer. MDMA reduced depressive symptoms in patients with life-threatening cancer, autism spectrum disorder, and post-traumatic stress disorder, and reduced social anxiety, but its effect on anxiety symptoms overall was negligible or negative. Ayahuasca reduced depressive symptoms in individuals with treatment-resistant major depressive and personality disorders. LSD reduced anxiety symptoms in individuals with life-threatening cancer. Adverse effects included elevated blood pressure, headaches, and panic attacks for psilocybin and MDMA, plus feeling cold for MDMA.
medRxiv
May 10, 2023
Victoria di Virgilio, Amir Minerbi, Jagpaul Kaur Deol et al.
preprint
Veterans and civilians who used psychedelic medicines for non-recreational purposes in the previous three years reported improvements across pain, mental health, function, and overall quality of life, with the largest perceived gains in mental health and quality of life and the smallest in pain. Correlations among these domains were highly significant, particularly between function, quality of life, and mental health. No significant differences emerged between specific psychedelic drugs, suggesting the benefits may be class-wide. The study was retrospective, anonymous, and relatively small (65 participants), and lacked a baseline comparison.
medRxiv
December 26, 2022
Jeremy Weleff, Akhil Anand, Elizabeth N. Dewey et al.
preprint
Lysergic acid (LSD) use in the United States rose by 47% from 2015 to 2019, from 0.59% to 0.87% of the population. However, among people reporting past-year hallucinogen use disorder, there was no significant proportional increase in LSD users. Correlates of LSD use included increased access, lower perceived risk, Asian race, low income, fewer children at home, history of selling drugs, recent drug solicitations, lack of religious influence on decisions, and past-year suicide attempt among adults. No associations were found with unemployment, arrest history, psychological distress, or sexually transmitted infections. The proportion of pregnant, married, and 26–34-year-old LSD users increased, as did LSD use among lifetime methamphetamine users.
medRxiv
June 16, 2022
Caroline L. Alves, Thaise G. L. de O. Toutain, Joel Augusto Moura Porto et al.
preprint
A machine-learning method using support vector machines classified EEG data from volunteers before and after inhaling the psychedelic DMT. Complex network measures derived from brain connectivity achieved 89% AUC, outperforming raw connectivity matrices. Key distinguishing features included connections between temporal and central cortex regions (TP8-C3) linked to finger movements, and between precentral gyrus and lateral occipital cortex (FC5-P8) potentially related to emotional and mystical experiences. Closeness centrality was the most important network measure. DMT increased community size and average path length, disrupting the balance between functional segregation and integration, supporting the idea that cortical activity becomes more entropic under psychedelics.
medRxiv
April 16, 2022
Yann Barguil, Laura Chiaradia, Guy Southwell et al.
preprint
Among young cannabis consumers, a brief psychotic disorder may signal either acute cannabis psychosis or the onset of schizophrenia, yet no clinical or paraclinical criteria reliably differentiate them. In a study of 256 New Caledonian cannabis users, delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in head hair were measured at initial psychiatric consultation and after a 6-month follow-up. A high hair THC level (>0.7 ng/mg) combined with a low CBD/THC ratio (<0.26) emerged as a potential marker for chronic psychosis. For acute cannabis psychosis, the CBD/THC ratio was higher (>0.43) than for other personality disorders (<0.32). The findings suggest CBD may protect against THC's harmful effects, and hair cannabinoid analysis could aid psychiatric diagnosis and early management.
medRxiv
March 2, 2022
Maggie Kiraga, Kim P. C. Kuypers, Malin V. Uthaug et al.
preprint
In a group of 52 healthy volunteers attending psilocybin ceremonies, consuming an average of 27.1 mg of psilocin led to medium to large reductions in both state and trait anxiety that persisted for at least one week. One week after the ceremony, participants showed increased non-judging mindfulness and decreased neuroticism. The strongest predictors of reduced trait anxiety were lower neuroticism, and for state anxiety, higher ego dissolution during the experience. The findings suggest rapid and lasting anxiolytic effects of psilocybin in a supportive setting, but further research is needed to confirm these effects in clinical populations.
medRxiv
January 31, 2022
Deepak Cyril D’souza, Justin Raj, Suhas Ganesh et al.
preprint
Male patients with new-onset Cannabis Induced Psychotic Disorder (CIPD) present with less severe psychotic symptoms and show greater improvement in both psychosis and cognitive deficits over four weeks of hospitalization compared to patients with psychosis unrelated to cannabis. Among 16 CIPD patients followed after discharge, 10 relapsed into psychosis within six months after resuming cannabis use. The findings suggest CIPD has a distinct short-term course with better acute resolution, but relapse of cannabis use may lead to poorer long-term outcomes. The study did not include female patients.
medRxiv
Klemens Egger, Daniel Meling, Firuze Polat et al.
preprint
In a double-blind, placebo-controlled pharmaco-fMRI study, 40 meditation practitioners on a three-day retreat received either placebo or buccal DMT-harmine (120 mg each). Meditation alone increased network segregation across several resting-state networks, while DMT-harmine increased functional connectivity within the visual network and between visual and attention networks. Between-group differences showed increased connectivity between visual and salience networks in the DMT-harmine group. No prolonged cortical gradient disruption was observed, indicating a return to typical brain organization shortly after the experience. Meditation reduced connectivity between networks, whereas DMT-harmine increased within- and between-network connectivity, revealing distinct neural mechanisms.